Last $2.30 USD
Change Today +0.18 / 8.49%
Volume 200.0
VGEN On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

vaccinogen inc (VGEN) Snapshot

Open
$2.30
Previous Close
$2.12
Day High
$2.30
Day Low
$2.30
52 Week High
01/9/14 - $11.00
52 Week Low
12/15/14 - $2.11
Market Cap
78.3M
Average Volume 10 Days
3.2K
EPS TTM
--
Shares Outstanding
34.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VACCINOGEN INC (VGEN)

Related News

No related news articles were found.

vaccinogen inc (VGEN) Related Businessweek News

No Related Businessweek News Found

vaccinogen inc (VGEN) Details

Vaccinogen Inc., a biotechnology company, focuses on the development and commercialization of cancer vaccines and immunotherapeutic products for cancers and infectious diseases. It primarily offers OncoVAX, a cancer vaccine for the post-surgical treatment of Stage II colon cancer. The company was founded in 2007 and is headquartered in Frederick, Maryland.

9 Employees
Last Reported Date: 03/28/14
Founded in 2007

vaccinogen inc (VGEN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $250.0K
Founder, Chairman Emeritus, Special Advisor, ...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

vaccinogen inc (VGEN) Key Developments

Vaccinogen, Inc. Announces Resignation of John Nicolis as a Director

On August 25, 2014, John Nicolis tendered his resignation as a director of Vaccinogen.

Vaccinogen, Inc. Announces Executive Changes

Vaccinogen, Inc. announced that Benjamin S. Carson, Sr., MD, an existing Vaccinogen Medical Advisory Board member, has been appointed to the Board of Directors and named Chairman of the Board. He is an Emeritus Professor of Neurosurgery, Oncology, Plastic Surgery and Pediatrics at the Johns Hopkins School of Medicine and serves on the board of directors of numerous organizations, including Kellogg's, and Costco. Vaccinogen co-founder and President Andrew L. Tussing, has been appointed to the Board of Directors and named Chief Executive Officer (CEO) to replace Michael G. Hanna, Jr., Ph.D., inventor of OncoVAX and co-founder of Vaccinogen. Dr. Hanna has stepped down as CEO and as Chairman of the Board effective as of the initial closing of a private placement. Dr. Hanna will continue to serve as a director and will now be Chairman Emeritus. Dr. Hanna will also remain on Vaccinogen's Medical Advisory Board and serve as special advisor to the CEO to assure his transfer of technical knowledge to new clinical and technical personnel to be hired for development of cancer therapeutic products. Mr. Halldin has been appointed to the Board of Directors as the TIS representative under which he will also serve as Vice Chairman. It is currently anticipated that Mr. Halldin will also serve as Chairman of the compensation, nominating and audit committees. Alan Cohen, Daniel Fitzgerald and Daniel Kane have each resigned from Vaccinogen's Board of Directors effective with this initial closing.

Vaccinogen, Inc. announced delayed 10-Q filing

On 08/15/2014, Vaccinogen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VGEN:US $2.30 USD +0.18

VGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VGEN.
View Industry Companies
 

Industry Analysis

VGEN

Industry Average

Valuation VGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VACCINOGEN INC, please visit www.vaccinogeninc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.